GlassScriptPhysician profile
Randy S Katz
NPI 1861455529
$3,617.30
in general payments reported to CMS, 2019-2025
23 companies · $716 in 2025
The $716 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $285 · 2021: $235 · 2022: $374 · 2023: $773 · 2024: $792 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,280.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,560.03 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $563.78 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $179.97 | 2023-2025 | Syfovre |
| Abbvie INC. | $162.03 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $151.44 | 2021-2023 | Cequa |
| Dompe US, INC. | $144.10 | 2020 | |
| Astellas Pharma US INC | $114.73 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.62 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $111.14 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Harrow Eye, LLC | $109.62 | 2024-2025 | Iheezo, Triesence |
| Novartis Pharmaceuticals Corporation | $103.71 | 2019-2021 | |
| Alcon Vision LLC | $53.33 | 2023-2025 | Simbrinza, Rocklatan |
| Bausch & Lomb Americas INC. | $46.22 | 2023-2024 | Miebo, Xipere, Lotemax Sm |
| Aerie Pharmaceuticals, INC. | $35.51 | 2021 | |
| Allergan, INC. | $34.03 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $25.13 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.34 | 2022 | |
| Neurotech Pharmaceuticals, INC. | $20.42 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.31 | 2025 | Opdualag |
| Tarsus Pharmaceuticals, INC. | $17.30 | 2024 | Xdemvy |
| Sight Sciences, INC. | $17.29 | 2022 | |
| Ocular Therapeutix, INC. | $11.25 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.